Serum bicarbonate as a marker to predict mortality in toxic epidermal necrolysis

Journal of Intensive Care Medicine

Volumn 26, Issue 4, 2011, Pages 250-254

  Yeong, Eng Kean ^a   Lee, Chao Hsiang ^a   Hu, Fu Chang ^a   Wu, M Z ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

mortality prediction; serum bicarbonate; toxic epidermal necrolysis

Indexed keywords

BICARBONATE; GLUCOSE; IMMUNOGLOBULIN; UREA;

ADULT; AGE; CLINICAL ARTICLE; DISEASE MARKER; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; INTENSIVE CARE; LEUKOPENIA; MALE; MORTALITY; PRIORITY JOURNAL; RARE DISEASE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; TACHYCARDIA; TOXIC EPIDERMAL NECROLYSIS; UREA BLOOD LEVEL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BICARBONATES; BIOLOGICAL MARKERS; CHILD; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PROGNOSIS; RISK ASSESSMENT; SEX FACTORS; SURVIVORS; TAIWAN; YOUNG ADULT;

EID: 80052078506     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066610390466     Document Type: Review

References (20)

1. Levi N., Bastuji-Garin S., Mockenhaupt M., et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009 ; 123 (2). e297 - e304.
2. Roujeau JC, Kelly JP, Naldi L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995 ; 333 (24). 1600-1607.
3. Roujeau JC, Guillaume JC, Fabre JP, Penso D., Fléchet ML, Girre JP Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990 ; 126 (1). 37-42. (Pubitemid 20040978)
4. Trent JT, Kirsner RS, Romanelli P., Kerdel FA Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol. 2004 ; 140 (7). 890-892. (Pubitemid 38917869)
5. Ducic I., Shalom A., Rising W., Nagamoto K., Munster AM Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg. 2002 ; 110 (3). 768-773. (Pubitemid 34855940)
6. Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol. 2005 ; 85 (6). 497-502. (Pubitemid 43087286)
7. Lebargy F., Wolkenstein P., Gisselbretcht M., et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997 ; 23 (12). 1237-1244. (Pubitemid 28017789)
8. Bastuji-Garin S., Fouchard N., Bertocchi M., Roujeau JC, Revuz J., Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000 ; 115 (2). 149-153. (Pubitemid 30637181)
9. Imahara SD, Holmes JH, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of standardized treatment protocol. J Burn Care Res. 2006 ; 27 (3). 270-275. (Pubitemid 43970289)
10. Creamer GL, Civil I., Koelmeyer T., Adams D., Cacala S., Thompson J. Population-based study of age, gender and causes of severe injury in Auckland, 2004. ANZ J Surg. 2008 ; 78 (11). 995-998.
11. Prins C., Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003 ; 139 (1). 26-32. (Pubitemid 36091570)
12. Rutherford EJ, Morris JA Jr, Reed GW, Hall KS Base deficit stratifies mortality and determines therapy. J Trauma. 1992 ; 33 (3). 417.
13. Davis JW, Shackford SR, Holbrook TL Base deficit as a sensitive indicator of compensated shock and tissue oxygen utilization. Surg Gynecol Obstet. 1991 ; 173 (6). 473-476.
14. Davis JW, Kaups KL Base deficit in the elderly: a marker of severe injury and death. J Trauma. 1998 ; 45 (5). 873-877. (Pubitemid 28524985)
15. French LE, Trent JT, Kerdel FA Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol. 2006 ; 6 (4). 543-549.
16. Stella M., Clemente A., Bollero D., Risso D., Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns. 2007 ; 33 (4). 452-459. (Pubitemid 46702386)
17. Bachot N., Revuz J., Roujeau JC Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003 ; 139 (1). 33-36. (Pubitemid 36091571)
18. Shortt R., Gomez M., Mittman N., Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004 ; 25 (3). 246-255. (Pubitemid 38637782)
19. Arevalo JM, Lorente JA Skin coverage with Biobrane biomaterial for the treatment of patients with toxic epidermal necrolysis. J Burn Care Rehabil. 1999 ; 20 (5). 406-410. (Pubitemid 29444969)
20. Bradley T., Brown RE, Kucan JO, Smoot EC 3rd, Hussmann J. Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Ann Plast Surg. 1995 ; 35 (2). 124-132.